著者: AultPatricia S, Rose PharmDJohn, Nodzon PhDLisa A, KaledElizabeth S

原題: Bosutinib Therapy in Patients With Chronic Myeloid Leukemia: Practical Considerations for Management of Side Effects.

著者: AslanNevin Alayvaz, HıncalHande Oğul, ElverÖzde, ErolVeysel, GülerNil

原題: Bosutinib-induced massive pleural effusion: Cross-intolerance with all tyrosine kinase inhibitors.

著者: BinzaidAbdulaziz A, BaqalOmar J, SoheibMohammed, Al NahedhMohammad, SamarkandiHadeel H, AljurfMahmoud

原題: Cardiovascular Toxicity Associated With Tyrosine Kinase Inhibitor Therapy In Chronic Myeloid Leukemia.

著者: KawanoNoriaki, KimuraShinya, MiuraMasatomo, TochigiTaro, NakaikeTakashi, YamashitaKiyoshi, MashibaKoichi, KikuchiIkuo, TakahashiNaoto

原題: Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Ph + ALL.

著者: LiuQiuying Selina, Ass'adNour Ali, Arana YiCecilia

原題: Bosutinib-associated interstitial lung disease and pleural effusion: A case report and literature review.

著者: HehlmannRüdiger

原題: The New ELN Recommendations for Treating CML.

著者: SerraoAlessandra, ScalzulliEmilia, FioriLuciano, Di PrimaAlessio, BrecciaMassimo, ChistoliniAntonio

原題: Concomitant Administration of Direct Oral Anticoagulants in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors.

著者: FachiMariana M, ToninFernanda S, LeonartLeticia P, RottaInajara, Fernandez-LlimosFernando, PontaroloRoberto

原題: Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: A network meta-analysis.

著者: García-GutiérrezValentín, MilojkovicDragana, Hernandez-BoludaJuan Carlos, ClaudianiSimone, Martin MateosMaría Luisa, Casado-MonteroLuis Felipe, GonzálezGloria, Jimenez-VelascoAntonio, BoqueConcepcion, Martinez-TrillosAlejandra, VázquezIsabel Mata, PayerÁngel Ramírez, SenínAlicia, Amustio DíezElena, GarcíaAbelardo Bárez, CarrascosaGuiomar Bautista, OrtíGuillermo, RuizBeatriz Cuevas, FernándezMaria Ángeles, Del Carmen García GarayMaría, GiraldoPilar, GuineaJose María, De Las Heras RodríguezNatalia, HernánNuria, PérezAna Iglesias, Piris-VillaespesaMiguel, LorenzoJose Luis López, Martí-TutusausJosep Maria Martí, VallansotRolando Omar, Ortega RivasFernando, PuertaJose Manuel, RamirezMaria Jose, RomeroEsperanza, RomoAndres, RosellAna, SaavedraSilvanna Saavedra, SebrangoAna, TallonJosé, ValenciaSandra, PorteroAngeles, SteegmannJuan Luis,

原題: Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients.

著者: IsfortSusanne, CrysandtMartina, GezerDeniz, KoschmiederSteffen, BrümmendorfTim H, WolfDominik

原題: Bosutinib: A Potent Second-Generation Tyrosine Kinase Inhibitor.

著者: IsfortSusanne, BrümmendorfTim H

原題: Bosutinib in chronic myeloid leukemia: patient selection and perspectives.

著者: RansohoffJulia D, KwongBernice Y

原題: Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies.

著者: WieSten M, WellbergElizabeth, KaramSana D, ReylandMary E

原題: Tyrosine Kinase Inhibitors Protect the Salivary Gland from Radiation Damage by Inhibiting Activation of Protein Kinase C-δ.

著者: ValentPeter, HerndlhoferSusanne, SchneeweißMathias, BoidolBernd, RinglerAnna, KubicekStefan, GleixnerKaroline V, HoermannGregor, HadzijusufovicEmir, MüllauerLeonhard, SperrWolfgang R, Superti-FurgaGiulio, MannhalterChristine

原題: TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML.

著者: DebS, SjöströmC, TharmakulanathanA, BoknäsN, LotfiK, RamströmS

原題: PO-55 - Individual variation in hemostatic alterations caused by tyrosine kinase inhibitors - a way to improve personalized cancer therapy?

著者: SamisJill, LeePaul, ZimmermanDonald, ArceciRobert J, SuttorpMeinolf, HijiyaNobuko

原題: Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia.

著者: CaldemeyerLauren, DuganMichael, EdwardsJohn, AkardLuke

原題: Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.

著者: CarneiroBenedito A, KaplanJason B, GilesFrancis J

原題: Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events.

著者: BrecciaMassimo, MolicaMatteo, AlimenaGiuliana

原題: How tyrosine kinase inhibitors impair metabolism and endocrine system function: a systematic updated review.

著者: SweetKendra, Pinilla-IbarzJavier, ZhangLing

原題: Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations.

著者: GiansantiPiero, PreisingerChristian, HuberKilian V M, GridlingManuela, Superti-FurgaGiulio, BennettKeiryn L, HeckAlbert J R

原題: Evaluating the promiscuous nature of tyrosine kinase inhibitors assessed in A431 epidermoid carcinoma cells by both chemical- and phosphoproteomics.

著者: IsfortSusanne, Keller-v AmsbergGunhild, SchafhausenPhilippe, KoschmiederSteffen, BrümmendorfTim H

原題: Bosutinib: a novel second-generation tyrosine kinase inhibitor.

著者: WallerCornelius F

原題: Imatinib mesylate.

著者: ShenAnn Q, WilsonNicole M, GleasonShannon L, KhouryHanna Jean

原題: Bosutinib in the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia: an overview.

著者: HaznedaroğluIbrahim C

原題: Current management of chronic myeloid leukemia with tyrosine kinase inhibitors.

著者: KantarjianHagop M, CortesJorge E, KimDong-Wook, KhouryH Jean, BrümmendorfTim H, PorkkaKimmo, MartinelliGiovanni, DurrantSimon, LeipEric, KellyVirginia, TurnbullKathleen, BessonNadine, Gambacorti-PasseriniCarlo

原題: Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.

著者: KhanAdeel M, BixbyDale L

原題: BCR-ABL inhibitors: updates in the management of patients with chronic-phase chronic myeloid leukemia.

著者: OkimotoRoss A, Van EttenRichard A

原題: Navigating the road toward optimal initial therapy for chronic myeloid leukemia.

著者: HuangXuan, PatelSamir, AhmedNasir, SeiterKaren, LiuDelong

原題: Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors.